The APOO Knockout A-549 Polyclonal Cells comprise a CRISPR/Cas9-edited polyclonal population derived from the human A-549 lung adenocarcinoma epithelial cell line, engineered to disrupt the APOO gene. This product provides a loss-of-function model for investigating the role of APOO (also known as MIC26), a critical subunit of the mitochondrial contact site and cristae organizing system (MICOS) complex. The polyclonal knockout format ensures a heterogeneous pool of gene-disrupted cells, enabling robust population-level analyses of mitochondrial phenotypes without the bottleneck effects associated with clonal selection.
The host A-549 cell line, isolated from a 58-year-old Caucasian male, is a widely used model for type II pneumocyte function and alveolar epithelium in lung adenocarcinoma research. These adherent epithelial cells maintain key characteristics of their tissue origin, including expression of surfactant proteins and metabolic pathways relevant to pulmonary biology. The A-549 background is particularly suited for studying mitochondrial dynamics in the context of non-small cell lung cancer, where metabolic reprogramming and apoptotic evasion are common features.
APOO functions as a stoichiometric component of the MICOS complex, directly interacting with core subunits such as MIC60/IMMT, MIC19/CHCHD3, MIC10/MINOS1, and MIC13/QIL1 to maintain cristae junction architecture and inner mitochondrial membrane organization. Upstream, APOO expression is regulated by mitochondrial biogenesis factors including PGC-1??, NRF1, and TFAM, integrating signals from cellular energy demand and mitochondrial stress. Disruption of APOO leads to downstream defects in MICOS complex assembly, altered cristae morphology, reduced ATP synthase activity, and aberrant cytochrome c release, thereby linking cristae integrity to both bioenergetics and intrinsic apoptosis. Representative pathway components affected include OPA1, SAM50, TOM40, TIM23, Bax, Bak, and cytochrome c.
In the A-549 lung cancer background, APOO knockout provides a powerful tool to dissect mitochondria-dependent processes in tumor cell survival and metabolism. Lung adenocarcinoma cells often exhibit altered mitochondrial ultrastructure and respiration to support proliferation; loss of APOO compromises cristae organization, sensitizing cells to metabolic stress and apoptotic stimuli. This model enables the study of how MICOS dysfunction influences oncogenic signaling, chemoresistance, and the balance between oxidative phosphorylation and glycolysis, with implications for mitochondrial disorders and metabolic diseases.
Researchers can employ this polyclonal knockout model in diverse applications, including high-resolution electron microscopy to visualize cristae morphology changes, western blotting to verify MIC60 and MIC19 complex integrity, and Seahorse metabolic flux analysis to assess oxygen consumption rates. Additional assays such as ATP bioluminescence measurements, JC-1 mitochondrial membrane potential assays, cytochrome c release ELISA, and caspase-3/7 activation tests allow detailed characterization of apoptotic and metabolic outcomes. The knockout cells are also suitable for high-throughput screening of compounds targeting MICOS assembly or mitochondrial function. For further information and technical support, please contact Ascent Research.
